Objectives: The objective of this study was to evaluate whether apparent diffusion coefficient (ADC) obtained through diffusion-weighted imaging magnetic resonance imaging at 3 T can be used as an imaging biomarker to differentiate invasive breast cancer from noninvasive ductal carcinoma in situ (DCIS). Materials and Methods: One hundred seventy-six histopathologically verified primary malignant breast tumors were retrospectively evaluated in 170 patients. All patients had undergone a standardized 3-T magnetic resonance imaging protocol, containing a diffusion-weighted sequence with 2 b values and a series of dynamic contrast-enhanced T1-weighted sequences. Apparent diffusion coefficient was measured manually by a reader blinded to the histopathological results. /s or less allowed an identification of invasive cancers with a sensitivity of 78.06% (95% CI, 70.7%-84.3%) and a specificity of 90.5% (95% CI, 69.6%-98.8%). No significant ADC differences were found among different tumor grades (P > 0.05). Conclusions: Apparent diffusion coefficient could be used as an imaging biomarker for the diagnosis of breast cancer. It seems to be a valuable noninvasive quantitative biomarker to assess breast cancer invasiveness. Thus, ADC measurements provide the potential to reduce overdiagnosis and subsequent overtreatment. Mammography screening in many countries has led to a substantial increase in the early detection of breast cancers.
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The ADC values were correlated with histopathological results. Mean ADC values were compared between invasive cancers and DCIS as well as between different tumor grades. Receiver operating characteristics curves were used to calculate diagnostic performance. /s or less allowed an identification of invasive cancers with a sensitivity of 78.06% (95% CI, 70.7%-84.3%) and a specificity of 90.5% (95% CI, 69.6%-98.8%). No significant ADC differences were found among different tumor grades (P > 0.05). Conclusions: Apparent diffusion coefficient could be used as an imaging biomarker for the diagnosis of breast cancer. It seems to be a valuable noninvasive quantitative biomarker to assess breast cancer invasiveness. Thus, ADC measurements provide the potential to reduce overdiagnosis and subsequent overtreatment.
Key Words: breast cancer, MRI, imaging biomarker, DWI, ADC (Invest Radiol 2015;50: 95-100) B reast cancer is the most common cancer in women worldwide. 1 Mammography screening in many countries has led to a substantial increase in the early detection of breast cancers. 2 However, higher detection rates have triggered a discussion about the problem of overdiagnosis. Overdiagnosis is the diagnosis of a disease that would otherwise not have caused symptoms or death and thus will lead to unnecessary overtreatment with all its attendant risks. 3 One possible source of overdiagnosis and subsequent overtreatment is the detection of noninvasive ductal carcinoma in situ (DCIS). This tumor type stems from the ductal epithelium of the breast and consists of neoplastic cells but does not infiltrate through the basal membrane. Although some DCIS will progress into invasive cancer, the percentage of DCIS becoming invasive is rather low. 4 Therefore, different approaches to avoid overtreatment in patients with DCIS are being investigated: although previous and ongoing studies examine the value of pharmacological intervention, 5, 6 another option would be watchful waiting instead of immediate surgery. This approach has shown promising results in supposedly nonaggressive prostate cancer 7, 8 and renal tumors [9] [10] [11] and is also currently being investigated for DCIS in the breast. 12 For a clinical adoption of this approach, a diagnostic test for differentiation of DCIS and invasive breast cancer is needed.
Imaging biomarkers are parameters that are objectively and quantitatively measured using imaging techniques, which can be used to either detect or characterize a disease. As opposed to histological or biochemical biomarkers, imaging biomarkers can be measured noninvasively and are spatially resolved. 13 One possible imaging biomarker for the differentiation between DCIS and invasive cancers is the quantitative apparent diffusion coefficient (ADC), obtained with diffusion-weighted imaging (DWI). Diffusion-weighted imaging measures the random movement of water molecules (ie, Brownian movement). Thus, it depicts the diffusivity of the examined tissues, providing a surrogate marker for tissue microstructure and cell density. 14, 15 Invasive cancers and DCIS show differences in microstructure: invasive cancers degrade tissue structure and spread unhindered through breast tissue by means of proteolytic activity. Ductal carcinoma in situ is restricted to the intraductal compartment; thus, the tissue between ducts is less affected by tumor growth. Tumor cells and chronic inflammatory reaction to proteolysis by means of desmoplastic tissue changes lead to a relative or absolute reduction in extracellular water content and may thus limit extracellular water diffusion. Both of these factors supposedly lead to decreased ADC of invasive cancer compared with noninvasive DCIS.
Thus, the aim of this study was to evaluate whether ADC obtained from DWI at 3 T can be used as an imaging biomarker for the differentiation of DCIS and invasive breast cancer.
MATERIALS AND METHODS

Patients
Our study was approved by the institutional review board of the Medical University Vienna, Vienna, Austria. Written informed consent was obtained from all patients.
Between September 2007 and December 2011, a total of 626 patients with mammography results of 0, 3, 4, or 5 according to the breast imaging-reporting and data system underwent 3-T breast magnetic resonance imaging (MRI) at our institution. Of these, 170 consecutive patients with 176 breast lesions who fulfilled the following inclusion criteria were retrospectively examined: 18 years or older and had histopathologically verified primary breast cancer and biopsy performed after MRI examination. The exclusion criteria were technical failure at DWI (n = 14) acquisition and recent prior needle biopsy of the breast or therapeutic breast procedure before MRI measurement.
Magnetic Resonance Imaging
All patients had undergone 3-T MRI (Tim Trio; Siemens, Erlangen, Germany) in prone position, using a 4-channel breast coil (InVivo, Orlando, FL). In premenopausal women, MRI had been performed in the second week of the menstrual cycle. 16 All patients had undergone a standardized MRI examination, including a T2-weighted sequence, a precontrast diffusion-weighted sequence, as well as a dynamic contrast-enhanced (0.1 mmol/kg body weight of Gadoteric Acid, Dotarem; Guerbet, Villepinte, France) high spatial and high temporal resolution T1-weighted sequence. 
Data Analysis
All measurements were performed by a radiologist trained in breast DWI analysis, under the supervision of an experienced breast radiologist, both of whom were blinded to the histopathological results.
High-b value (ie, 850 s/mm 2 ) DWI images and contrast-enhanced MRI were visually assessed for hyperintense regions corresponding to enhancing lesions on contrast-enhanced MRI. OSIRIX 18 was used for the assessment of the ADC maps. One 2-dimensional region of interest (ROI) was drawn manually on the ADC maps in all lesions, covering the area with the lowest ADC values inside the lesion. Partial volume effects due to normal parenchyma and areas of necrotic tissue were avoided. The mean ADC of the ROI was determined. Lesion size was measured using contrast-enhanced MRI.
The reference standard for MRI findings was histopathology in all cases. Histopathologic specimens were obtained by either imageguided biopsy or open surgery. Histopathological analysis was performed by 2 board-certified pathologists specializing in breast pathology in each case. Diagnostic procedures were performed according to the European guidelines for quality assurance in breast cancer screening and diagnosis. 19 
Statistical Analysis
Statistical analysis was performed using Statistical Package for the Social Sciences 19.0 (IBM Corp, Armonk, NY), CIA (University of Southampton, Southampton, United Kingdom) 2.2.0, and MedCalc 12 (MedCalc Software, Ostend, Belgium). All calculations were performed on a per-lesion basis. Nominal data such as tumor type are presented using absolute frequencies and percentages. Metric data such as ADC are presented as mean (SD). Differences in average ADC values for different groups were calculated using either unpaired t tests (2 groups) or 1-way analysis of variance (more than 2 groups) given homogeneous variances. Lesion size and ADC were correlated using the Pearson test. In case of heterogeneous variances, the Welch corrected t tests and analyses of variances were applied. Homogeneity of variances was tested using Levene tests. Receiver operating characteristics analysis with the Youden J statistics was performed for calculation thresholds. By varying the diagnostic ADC threshold to differentiate between DCIS and invasive lesions, rule-in and rule-out criteria for cancer invasiveness were identified, with exemplary thresholds to reach greater than 90% sensitivity and greater than 90% specificity. A P value ≤ 0.05 was considered to indicate a significant result.
RESULTS
Mean (SD) age of the included patients was 56.0 (12.8) years (range, 26-87 years).
ADC Values and Histopathology
Histopathological results are shown in Figure 1 . An overview on the ADC values for the different tumor subtypes is shown in Table 1 .
Overall, DCIS (Fig. 2) showed significantly higher ADC values than invasive cancers did (Fig. 3) (P < 0.001). This holds true for invasive ductal cancers (IDCs) (P < 0.001) and invasive lobular cancers (P < 0.001). No significant difference could be seen between IDC and invasive lobular cancer (P = 0.805) (Fig. 4) .
The receiver operating characteristics analysis found an area under the curve (AUC) of 0. (Fig. 5) .
Nineteen lesions presented as non-mass lesions on the dynamic contrast-enhanced images (13 invasive cancers, 6 DCIS), whereas 157 were mass lesions (142 invasive cancers, 15 DCIS). Overall, mean ADC values were significantly different between the mass and nonmass lesions (P = 0.031). Invasive cancers and DCIS also demonstrated significant differences in mean ADC in the mass subgroup (P < 0.001) and in the non-mass subgroup (P = 0.001). The AUC for the differentiation of invasive cancers and DCIS was 0.865 for the mass and 0.974 for the non-mass subgroup.
The mean ADC values of the different tumor grades are displayed in Table 1 . The ADC values did not differ significantly between the tumor grades neither in the invasive (P = 0.272) nor in the DCIS group (P = 0.593).
Mean lesion size was 29.8 mm. There was no significant difference between the mean lesion size of invasive cancers (30 mm; range, 5-100 mm) and DCIS (28.1 mm; range, 9-90 mm) (P = 0.692). In addition, no correlation could be found between lesion size and ADC (r = 0.33, P = 0.661).
DISCUSSION
Imaging biomarkers are parameters that are objectively and quantitatively measured using imaging techniques, which can be used to either detect or characterize a disease. In contrast, conventional morphologic imaging features, such as lesion shape, margin, or distribution pattern, are often heavily dependent on the reader, leading to considerable interobserver variabilities, 20 and are less accurate. The data of our study show that ADC seems to be a useful noninvasive imaging biomarker for the prediction of breast cancer invasiveness. The mean ADC is significantly different between invasive breast cancer and DCIS (P < 0.001). Thus, a differentiation between these 2 cancer groups is enabled with high diagnostic accuracy (Fig. 5) . Apparent diffusion coefficient as a continuous metric measure represents different probabilities of cancer invasiveness depending on the individually measured ADC value. By flexible use of 2 different ADC threshold values, we could identify invasive from noninvasive cancers with a respective certainty of 90% or greater. At the upper threshold, the sensitivity for diagnosis of invasive cancer is greater than 90%, meaning that 9 of 10 invasive cancers will show ADC values equal to or below this threshold. If ADC values are equal to or lower than the lower threshold, only 1 of 10 lesions diagnosed as invasive cancer is actually DCIS, thus allowing a specific diagnosis of invasive cancer.
Mean ADC values in our study were significantly higher in the non-mass-enhancing lesions than in the mass lesions. This is in concurrence with the literature. 21 However, differentiation of invasive cancer and DCIS was also possible in each subgroup, with an even better performance in the non-mass-enhancing lesions, reaching an AUC of 0.974 in this somewhat problematic entity. 22 Overdiagnosis and subsequent overtreatment are increasingly discussed in patients with breast cancer. There is more and more evidence that some cancer types, particularly DCIS, show low biological aggressiveness and can thus be treated less aggressively. Here, the role of pharmacological intervention 6 or watchful waiting instead of immediate surgery is currently investigated. 12 This approach is not new and has shown promising results in renal and prostate cancer. [7] [8] [9] [10] [11] Our results are of great clinical importance because they prepare the ground for potential watchful waiting approaches on DCIS lesions. For therapeutic decisions, the presence of DCIS has to be verified at all times. Magnetic resonance imaging would be a suitable tool before decision making and could be used for follow-ups of DCIS under either antihormonal treatment or watchful waiting. The ability of DWI to provide data for this task is beneficial because ADC values are quantitative and, thus, objective. Furthermore, DWI is a short examination without a need for contrast agent injection, thereby minimizing examination costs.
Although previous studies have also indicated ADC differences between invasive breast cancer and DCIS (Table 2) , to our knowledge, only 1 group has so far tried to establish thresholds to differentiate invasive breast cancer from DCIS using ADC. Mori et al 33 used ADC to identify invasive components in breast tumors histopathologically classified as DCIS and found that minimum ADC as well as the difference between minimum and maximum ADC could differentiate pure DCIS from DCIS with invasive components, reaching sensitivities of 72% and 68% and specificities of 77% and 76%, respectively. (Table 2 ). These heterogeneities can probably be attributed to differences in examination protocols and ADC measurement. Furthermore, significant ADC differences have been shown to occur when working with different field strengths. 34 However, the majority of previous studies showed significant ADC differences between DCIS and invasive cancer ( Table 2 ). This suggests that standardized measurement protocols will be needed for clinical applications and that separate thresholds will be needed for different scanners, protocols, and field strengths. 13 Regarding tumor grade, we did not find significant ADC differences in both DCIS and invasive cancers. This finding is consistent with the results published by Rahbar et al. 35, 36 On the other hand, Iiama et al 37 found a significant difference in minimum ADC between lowgrade and combined intermediate and high-grade cancers. Because the number of patients for each tumor grade is rather low in all of the aforementioned studies, as well as that in our study, further investigation with larger numbers of patients may be required. It may be assumed that technical advances such as diffusion tensor imaging or combined multiparametric assessment of breast lesions including contrast-enhanced scans might improve diagnosis of tumor grade. [38] [39] [40] There are some limitations to our study. With only 1 DWI reader, reproducibility of the results could not be evaluated further. In addition, the ADC measurements were performed by placing manually drawn ROIs in the area with the, visually assessed, region with the lowest ADC value inside the tumor, which could lead to reduced reproducibility of our results. However, a previous work demonstrated excellent interobserver agreement for repeated ADC measurements of the breast using this ADC-measurement approach. 41 The relatively low number of DCIS (11.9% of all cancers) included in our study may be seen as another limitation because DCIS, nowadays, accounts for approximately 20% to 25% of diagnosed breast cancers in the United States. 2 This discrepancy can be attributed to the fact that our institution is a major breast care center and patients are referred either because of symptomatic breast tumors or for second-look examinations after imaging abnormalities were detected in other institutions. Thus, our study population does not recruit from a screening population, explaining the lower prevalence of DCIS. 42 Nevertheless, the rather low prevalence of DCIS in our study does not limit the validity of the substantial differences in quantitative ADC values between DCIS and invasive cancers found in our study. Fourteen (7.6%) patients had to be excluded because of imaging artifacts. Artifacts that led to unevaluable DWI images were mainly geometric distortions and ghosting artifacts, each of which can occur frequently in single-shot EPI DWI sequences, especially when using higher field strengths. 23 One possible solution could be the use of readout-segmented EPI sequences, in which geometric distortions, blurring, and ghosting artifacts are reduced as compared with singleshot EPI at 3 T. 41 In conclusion, we found that ADC seems to be a valuable noninvasive, quantitative imaging biomarker to assess breast cancer invasiveness. Thus, ADC provides the potential to reduce overdiagnosis and subsequent overtreatment. This article may be seen as another step toward a completely noninvasive imaging-based characterization of breast cancer. 
